Tulathromycin
Systematic (IUPAC) name | |
---|---|
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-Ο-methyl-4-C-[(propylamino)methyl]-α-L-ribo-hexopyrano-syl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]-oxy]-1-oxa-6-azacyclopentadecan-15-one | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
217500-96-4 | |
QJ01FA94 | |
ChemSpider | 24583287 |
UNII | Q839I13422 |
KEGG | D06258 |
Chemical data | |
Formula | C41H79N3O12 |
806.08 g/mol | |
SMILES
| |
| |
(what is this?) (verify) |
Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs. It is marketed by Pfizer Inc. under the tradename Draxxin.
It is supplied as a solution for injection containing 100 mg of the drug. [1]